Last update Aug. 3, 2022


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Fosfomycin is a bactericidal antibacterial indicated in the treatment of uncomplicated acute cystitis in adult women and adolescents. One to three time daily oral administration for one to three days. Possible intravenous administration.

It is excreted in human milk in insignificant amounts. (Kirby 1977)

Its use is approved in infants less than one year of age.

Its low oral bioavailability makes it difficult for the infant to pass into plasma from ingested mothers’ milk, except in premature infants and during the immediate neonatal period in which there may be greater intestinal permeability.

Food and calcium in the mothers’ milk make intestinal absorption even more difficult (Hale); calcium fosfomycin is very poorly absorbed. (Lebedevs 2020, Bergan 1990)

Although rare, the possibility of transient gastroenteritis due to altered intestinal flora should be considered in infants whose mothers take antibiotics. (Briggs 2015, Benyamini 2005)


We do not have alternatives for ホスホマイシントロメタミン since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

ホスホマイシントロメタミン is Fosfomycin Trometamol, Fosfomycin Tromethamine in Japanese.

Is written in other languages:

ホスホマイシントロメタミン is also known as


ホスホマイシントロメタミン belongs to this group or family:


Main tradenames from several countries containing ホスホマイシントロメタミン in its composition:


Variable Value Unit
Oral Bioavail. Trom: 30 - 58; Calc: 12 %
Molecular weight 259 daltons
Protein Binding 1 %
VD 1.9 ± 0.6 l/Kg
pKa 1.25 -
Tmax 2 - 4 hours
4 - 6 hours
M/P ratio 0.1 -
Theoretical Dose 0.54 - 0.72 mg/Kg/d
Relative Dose 1.6 - 4.3 %
Ped.Relat.Dose 0.27 - 0.72 %


  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  2. AEMPS Fosfomicina Ficha técnica 2020 Full text (in our servers)
  3. Lebedevs T. Fosfomycin and breastfeeding. Aust Prescr. 2020 Aug;43(4):113. Abstract Full text (link to original source)
  4. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  5. FDA. Fosfomycin Drug Summary 2007 Full text (in our servers)
  6. Gobernado M. [Fosfomycin]. Rev Esp Quimioter. 2003 Abstract Full text (link to original source) Full text (in our servers)
  7. Bergan T. Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives. Chemotherapy. 1990 Abstract
  8. Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection. 1990 Abstract
  9. Kirby WM. Pharmacokinetics of fosfomycin. Chemotherapy. 1977 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM